These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16935904)

  • 21. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D
    Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Darbepoetin in the treatment of the renal anaemia in the patient undergoing peritoneal dialysis previously treated with epoetin alfa].
    Remón C; Quirós P; Fernández Marchena D; Hernández Romero M; del Castillo R; Fernández Ruiz E
    Nefrologia; 2005; 25(2):170-7. PubMed ID: 15912654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study.
    Bommer J; Asmus G; Wenning M; Bommer G
    Nephrol Dial Transplant; 2008 Dec; 23(12):4002-8. PubMed ID: 18676350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha.
    Walker R; Pussell BA;
    Nephrology (Carlton); 2009 Oct; 14(7):689-95. PubMed ID: 19796029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching from epoetin alpha to darbepoetin alpha in Japanese hemodialysis patients: dose conversion ratio.
    Hirai T; Sugiya N; Nakashima A; Takasugi N; Yorioka N
    Nephron Clin Pract; 2009; 111(2):c81-6. PubMed ID: 19088483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis.
    Allon M; Kleinman K; Walczyk M; Kaupke C; Messer-Mann L; Olson K; Heatherington AC; Maroni BJ
    Clin Pharmacol Ther; 2002 Nov; 72(5):546-55. PubMed ID: 12426518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin.
    Veys N; Vanholder R; Lameire N
    Am J Nephrol; 1992; 12(1-2):68-72. PubMed ID: 1415368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease.
    Lerner G; Kale AS; Warady BA; Jabs K; Bunchman TE; Heatherington A; Olson K; Messer-Mann L; Maroni BJ
    Pediatr Nephrol; 2002 Nov; 17(11):933-7. PubMed ID: 12432437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of different dialysis membranes on serum concentrations of epoetin alfa, darbepoetin alfa, enoxaparin, and iron sucrose during dialysis.
    McMahon LP; Chester K; Walker RG
    Am J Kidney Dis; 2004 Sep; 44(3):509-16. PubMed ID: 15332224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
    Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
    Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluctuations in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa.
    Walker R; Pussell BA;
    Nephrology (Carlton); 2007 Oct; 12(5):448-51. PubMed ID: 17803467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients.
    Cervelli MJ; Gray N; McDonald S; Gentgall MG; Disney AP
    Nephrology (Carlton); 2005 Apr; 10(2):129-35. PubMed ID: 15877671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.
    Raymond CB; Wazny LD; Vercaigne LM; Lesperance EM; Skwarchuk DE; Bernstein KN
    CANNT J; 2008; 18(1):39-43. PubMed ID: 18435363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa.
    Aarup M; Bryndum J; Dieperink H; Joffe P
    Nephrol Dial Transplant; 2006 May; 21(5):1312-6. PubMed ID: 16396971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
    Wanic-Kossowska M
    Pol Merkur Lekarski; 2010 Jan; 28(163):13-7. PubMed ID: 20369716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO)].
    Del Vecchio L; Villa G; Carraro G; Morosetti M; Pedrini L; Adorati Menegato M; Amato M; Mauro MM; Borgatti P; Malberti F; Marai P; Locatelli F;
    G Ital Nefrol; 2004; 21(3):259-66. PubMed ID: 15285005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.